Test Blog Page

According to TMR analysts, the global erectile dysfunction drugs market is likely to decline at a 3.2% CAGR over the forecast period 2018 to 2026. The market was estimated to be worth US$4.35 Bn in 2016 and is prognosticated to reach a value of US$ 2.87 Bn by 2026. Based on the product, Viagra segment led the global erectile dysfunction drugs market until the beginning of the forecast period. The expiry of the patent dealt a severe blow to the segment’s
Two e-cigarette liquids contain undisclosed prescription drugs that treat erectile dysfunction and should not be used, the Food and Drug Administration (FDA) said in a warning Wednesday. The two HelloCig e-liquids contain tadalafil and sildenafil, the main ingredients in two of the most popular male enhancement drugs on the market, the FDA said. “These FDA-approved prescription drugs are not approved for inclusion in e-liquid products sold over the counter and are therefore being sold illegally. The drugs
A generic version of Cialis® (Eli Lilly) tadalafil tablets (2.5 mg, 5 mg, 10 mg, 20 mg) for the United States market has been annouced by Teva Pharmaceuticals, in a first-to-file launch. Tadalafil tablets are a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction (ED), the signs and symptoms of benign prostatic hyperplasia (BPH), and both ED and the signs and symptoms of BPH (ED/BPH). Tadalafil tablets are recommended for use up to
Aquestive Therapeutics has received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) in regards to its New Drug Application (NDA) for tadalafil oral film (OF). Tadalafil is a PDE5 inhibitor currently marketed in tablet form for the treatment of erectile dysfunction and benign prostatic hyperplasia (BPH) under the brand name Cialis, and for treatment of pulmonary arterial hypertension under the brand name Adcirca. In the letter, the FDA requested limited
-Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company, announced today that the Company has dosed its first patient for its bioequivalence study of Tadalafil (Cialis®) and Finasteride (PROSCAR®) combination tablet for benign prostatic hyperplasia (BPH) (Tad-Fin Combination Tablet).  Tad-Fin Combination Tablet is designed for the co-administration of tadalafil and finasteride to improve patient compliance and convenience for men suffering from BPH.  Finasteride shrinks the prostate while tadalafil treats the symptoms of BPH.  The